Topline Score

Bio

Generated by
Topline AI

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.

0

/5.0
/ Based on 0 ratings
  • (0)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

No reviews to display There are currently no reviews available.
You need to have a working account to view this content. Click here to join now

Experience

    • United Kingdom
    • Pharmaceutical Manufacturing
    • 1 - 100 Employee
    • Director & Co Founder
      • Oct 2019 - Present

      Inventa is a bio pharmaceutical company which is developing novel formulations of existing compounds to better treat a variety of established medical needs that are currently poorly served. The company’s development pipeline is currently focused on novel pro-drugs to treat certain inflammatory and genetic disorders. Having completed its first in-licensing deal and seed funding, the company is actively seeking new in-licensing opportunities and additional funding. Inventa is a bio pharmaceutical company which is developing novel formulations of existing compounds to better treat a variety of established medical needs that are currently poorly served. The company’s development pipeline is currently focused on novel pro-drugs to treat certain inflammatory and genetic disorders. Having completed its first in-licensing deal and seed funding, the company is actively seeking new in-licensing opportunities and additional funding.

    • Director & Co Founder
      • Feb 2020 - Present

      AlternOx is a newly established University of Sussex (UoS) spin-out, focused on the exploitation of novel and proprietary inhibitors of alternative oxidase (AOX) to treat a wide range of multi-drug and multi compound resistant species of fungi that now threaten human health and food security worldwide AlternOx is a newly established University of Sussex (UoS) spin-out, focused on the exploitation of novel and proprietary inhibitors of alternative oxidase (AOX) to treat a wide range of multi-drug and multi compound resistant species of fungi that now threaten human health and food security worldwide

    • United Kingdom
    • Accounting
    • Managing Director
      • Nov 2015 - Present

      I set up my own consultancy company Brosnaich Ventures Limited in November 2015 to provide services to early stage growth companies in the biotech/ medical / technology sectors that require the skills and knowledge of an experienced CFO. I set up my own consultancy company Brosnaich Ventures Limited in November 2015 to provide services to early stage growth companies in the biotech/ medical / technology sectors that require the skills and knowledge of an experienced CFO.

    • Invited Lecturer
      • Oct 2018 - Present

      Deliver finance lectures for the Technology and Innovation Management Module as part of the MPhil in Bioscience Enterprise (MBE) at the University of Cambridge. Deliver finance lectures for the Technology and Innovation Management Module as part of the MPhil in Bioscience Enterprise (MBE) at the University of Cambridge.

    • United Kingdom
    • Medical Equipment Manufacturing
    • CFO
      • Dec 2015 - Apr 2020

      Pertinax provides sustained, controlled antimicrobial protection for medical devices, biomaterials and in topical formulations. The Company was spun out of the University of Bristol in 2015 and is privately funded. Pertinax provides sustained, controlled antimicrobial protection for medical devices, biomaterials and in topical formulations. The Company was spun out of the University of Bristol in 2015 and is privately funded.

    • United Kingdom
    • Biotechnology Research
    • 1 - 100 Employee
    • CFO
      • Dec 2015 - Dec 2019

      CMD is a Cardiff based diagnostics company, developing a rapid and novel point-of-need analytical platform based on proprietary intellectual property. This technology has initially been applied to the rapid and sensitive detection of bacterial endotoxins. CMD is a Cardiff based diagnostics company, developing a rapid and novel point-of-need analytical platform based on proprietary intellectual property. This technology has initially been applied to the rapid and sensitive detection of bacterial endotoxins.

    • United Kingdom
    • CFO
      • Jun 2016 - Jul 2017

    • United Kingdom
    • Aviation and Aerospace Component Manufacturing
    • 1 - 100 Employee
    • CFO
      • Dec 2015 - Dec 2016

      Aveillant (now part of Thales) was a Cambridge based spin out company from Cambridge Consultants developing holographic radar technology. The technology was originally developed for wind farm mitigation but changed strategy to drone detection. Aveillant (now part of Thales) was a Cambridge based spin out company from Cambridge Consultants developing holographic radar technology. The technology was originally developed for wind farm mitigation but changed strategy to drone detection.

    • United Kingdom
    • Oil and Gas
    • 1 - 100 Employee
    • CFO
      • Aug 2008 - Nov 2015

      Privately backed growth technology company. ARKeX was a geophysical service company for the oil & gas industries, helping explorationists obtain a better understanding of their subsurface geology.ARKeX acquire, process and interpret gravity gradiometry data in both airborne and marine environments. Privately backed growth technology company. ARKeX was a geophysical service company for the oil & gas industries, helping explorationists obtain a better understanding of their subsurface geology.ARKeX acquire, process and interpret gravity gradiometry data in both airborne and marine environments.

    • CFO (Part time)
      • Jul 2008 - Jan 2009

      CFO on part time basis (in parallel with initially a part time interim role at ARKeX) for an early stage technology company that was spin out from Phillip’s developing new screen display technology for mobile devices. Operations based in Eindhoven & Hong Kong. Company since acquired by Amazon CFO on part time basis (in parallel with initially a part time interim role at ARKeX) for an early stage technology company that was spin out from Phillip’s developing new screen display technology for mobile devices. Operations based in Eindhoven & Hong Kong. Company since acquired by Amazon

    • Congo
    • IT Services and IT Consulting
    • 1 - 100 Employee
    • EVP & Group Finance Director
      • Aug 2006 - Jun 2008

      Sosei is a publicly traded Japanese biopharmaceutical company based in Tokyo. In August 2005 Sosei acquired Arakis Ltd, which at that time was one of the leading European venture capital funded biotech companies. Following the acquisition of Arakis for £106M, I was appointed Sosei Group Finance Director and EVP in 2006. Sosei is a publicly traded Japanese biopharmaceutical company based in Tokyo. In August 2005 Sosei acquired Arakis Ltd, which at that time was one of the leading European venture capital funded biotech companies. Following the acquisition of Arakis for £106M, I was appointed Sosei Group Finance Director and EVP in 2006.

    • Director of Finance
      • Dec 2001 - Aug 2006

      I started working for Arakis Ltd shortly after it was founded in 2000 and was the first employee of the company with any financial experience. Part of the management team that culminated in the sale of the company to Sosei in 2005. Company name changed to Sosei R&D after the acquisition. I started working for Arakis Ltd shortly after it was founded in 2000 and was the first employee of the company with any financial experience. Part of the management team that culminated in the sale of the company to Sosei in 2005. Company name changed to Sosei R&D after the acquisition.

    • Finance Director
      • 1999 - 2001

      This was a new position created as a result of the company’s growth as a distributor of packaging, processing and security machinery for the pharmaceutical and healthcare industries. This was a new position created as a result of the company’s growth as a distributor of packaging, processing and security machinery for the pharmaceutical and healthcare industries.

    • Group Finance Manager
      • 1997 - 1999

      A UK quoted company in the controls technology market, with fully autonomous subsidiary operations in the UK and USA (Turnover ~ £100M). Part of a small head office team, reporting to the Group Finance Director. A UK quoted company in the controls technology market, with fully autonomous subsidiary operations in the UK and USA (Turnover ~ £100M). Part of a small head office team, reporting to the Group Finance Director.

    • Industrial Machinery Manufacturing
    • 700 & Above Employee
    • Financial Accounting Manager
      • 1992 - 1997

      Worked in the division responsible for the worldwide distribution for diesel engines and aftermarket sales and support, with sales of > £200m in 160 countries. Initial role for 2½ years was a new project management position before moving into a line management role as the Financial Accounting Manager. Worked in the division responsible for the worldwide distribution for diesel engines and aftermarket sales and support, with sales of > £200m in 160 countries. Initial role for 2½ years was a new project management position before moving into a line management role as the Financial Accounting Manager.

    • Professional Services
    • 700 & Above Employee
    • Audit
      • 1988 - 1992

      Usual array of audit and corporate finance projects. Qualified as ACA in 2001 with first time pass record. Usual array of audit and corporate finance projects. Qualified as ACA in 2001 with first time pass record.

Education

  • University of Strathclyde
    BA (Hons), Economics & Marketing
    1984 - 1988

Community

You need to have a working account to view this content. Click here to join now